1. Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
- Author
-
Swinburn P, Shingler S, Acaster S, Lloyd A, and Bonthapally V
- Subjects
- Adult, Australia, Brazil, Female, Health Surveys methods, Humans, Male, Mexico, Middle Aged, Outcome Assessment, Health Care methods, Quality of Life, Quality-Adjusted Life Years, Republic of Korea, Surveys and Questionnaires, Taiwan, Thailand, United Kingdom, Young Adult, Health Services statistics & numerical data, Health Surveys statistics & numerical data, Hodgkin Disease therapy, Lymphoma, Large-Cell, Anaplastic therapy, Outcome Assessment, Health Care statistics & numerical data
- Abstract
New therapies for relapsing/refractory Hodgkin lymphoma (R/R HL) and R/R systemic anaplastic large-cell lymphoma (sALCL) have emerged. This study captured utility values for R/R HL and sALCL to support economic evaluation. Health state "vignettes" were developed describing states associated with R/R HL and sALCL: treatment response (complete or partial response), stable and progressive disease and treatment-related adverse events (B-symptoms, acute/chronic graft-versus-host disease [GVHD] and peripheral neuropathy). Vignettes were evaluated by members of the public in the UK, Australia, Taiwan, Thailand, South Korea, Brazil and Mexico using the time trade-off method. Mean utilities varied substantially. Complete response utility scores were UK: 0.906, Australia: 0.889, Taiwan: 0.597, Thailand: 0.728, South Korea: 0.827, Brazil: 0.764, Mexico: 0.728. Adverse events were associated with disutility: acute GVHD, lowest mean utility value: Thailand 0.124; highest value: Mexico 0.467. Societal evaluation of health states for R/R HL and sALCL revealed a marked perceived benefit of a treatment response.
- Published
- 2015
- Full Text
- View/download PDF